Results 91 to 100 of about 3,343,278 (165)
Mucuna pruriens as a Sustainable Functional Food: Applications From Seed to Product
This review highlights Mucuna pruriens as a nutrient‐rich legume with significant nutritional, therapeutic, and agricultural value. Its protein‐rich seeds contain essential minerals and L‐DOPA, but high antinutritional compounds require effective processing before consumption.
Crossby Osei Tutu +10 more
wiley +1 more source
The aim of the present study was to evaluate the role of the nitric oxide/cyclic guanosine monophosphate pathway in corticostriatal long-term depression induction in a model of levodopa-induced dyskinesia in experimental parkinsonism.
Calabresi, Paolo +22 more
core +1 more source
Long-term treatment of Parkinson's disease with levodopa is complicated by the emergence of involuntary movements, known as levodopa-induced dyskinesia.
Crossman, Alan R. +3 more
core +1 more source
Safinamide modulates striatal glutamatergic signaling in a rat model of levodopa-induced dyskinesia
Safinamide (Xadago) is a novel dual-mechanism drug that has been approved in the European Union and United States as add-on treatment to levodopa in Parkinson's disease therapy.
Novello S. +12 more
core +2 more sources
Hyperdopaminergic Manifestations in Parkinson’s Disease: Correlation between Impulse Control Disorders and Levodopa- Induced Dyskinesia [PDF]
Objective: To explore the relationship between levodopa-induced dyskinesia and impulse control disorders (ICDs) inParkinson’s disease (PD), exploring the hyperdopaminergic motor and non-motor state.Methods: A cross-sectional study was conducted on 30 PD ...
ALIA MANSOUR +4 more
doaj +1 more source
BACKGROUND: It remains controversial whether late levodopa administration is a reasonable approach to reducing the risk of levodopa-induced dyskinesia in Parkinson's disease. OBJECTIVE: This study aimed to investigate the effects of levodopa sparing
이필휴 +4 more
core +1 more source
A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia [PDF]
BackgroundThis phase 2 randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of the nicotinic acetylcholine receptor 7 agonist AQW051 in patients with Parkinson's disease and levodopa-induced dyskinesia.
Jaeger, J +65 more
core +1 more source
No New Relevant Treatment Options for L-DOPA-Induced Dyskinesia from a Clinician’s Point of View
Background: The term dyskinesia describes involuntary movements of the face, body and extremities. Frequently, they appear following and in relation with prior oral long-lasting and high-dose levodopa therapy in Parkinson’s disease patients.
Thomas Müller
doaj +1 more source
Transcriptome‐Based Identification of ZZEF1 and ENTPD5 as Candidate Genes for Dystonia
Movement Disorders, EarlyView.
Alexandra Rudnik +15 more
wiley +1 more source
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.
OBJECTIVE:: Striatal serotonin projections have been implicated in levodopa-induced dyskinesia by providing an unregulated source of dopamine release.
Dovero, Sandra +18 more
core +1 more source

